Identify the business objective
State whether the project concerns CMO, CDMO, technology transfer, product and registration cooperation, or another defined opportunity.
Global pharmaceutical partnership workspace
Move from a public question
to a controlled project decision.
Use this workspace to check public capability scope, prepare a non-confidential project brief, understand the NDA pathway and request a preliminary assessment.
Begin with facts that can be safely shared
A useful first conversation does not need formulas, dossiers, patient information or trade secrets. It needs enough context to decide whether a focused assessment is responsible.
Describe the project at a high level
Provide the dosage form, target market, project stage, presentation, indicative timing and a short non-confidential objective.
Check the public platform scope
Review the confirmed dosage-form platforms and the limits of public information before assuming product or capacity fit.
Choose the confidentiality gate
Use the initial form for non-confidential facts. Exchange technical packages only after a mutual NDA and agreed request list.
Partner fit
Start from the role your organization will hold.
This public workspace is designed for B2B pharmaceutical cooperation. It helps a prospective partner decide whether a focused, non-confidential project discussion is appropriate before either side commits resources or shares controlled information.
Product owner / MAH
Product, portfolio or supply-route review
For an organization assessing commercial manufacturing, scale-up, product continuity, a development route or a controlled manufacturing transfer.
Market-access partner
Registration and market-entry discussion
For an organization with a defined role in a target market that needs to assess a product, manufacturing, registration or cooperation path at a high level.
Technology or manufacturing partner
Transfer and responsibility planning
For a team exploring a controlled technology-transfer or manufacturing collaboration route, including the evidence, responsibilities and confidentiality gate required before technical exchange.
This is not a patient, prescription, product-use, pharmacovigilance, employment or consumer-service channel. It supports organization-to-organization pharmaceutical project discussions only.
Self-qualification
Project readiness self-check
Before submitting an inquiry, a prospective partner should be able to answer most of these questions without exposing confidential information.
- Which legal entity is making the inquiry and what role will it hold in the target market?
- Which dosage form, presentation and high-level product route are relevant?
- Which market or markets are being considered?
- Is the project at early evaluation, development, scale-up, registration, commercial supply or transfer planning?
- Which cooperation model is being explored: CMO, CDMO, technology transfer, product and registration cooperation, or another path?
- What decision, milestone or timing window makes an initial assessment useful now?
Choose a starting route
Start with the decision you need to make now.
Choose a route to preselect the cooperation model in the inquiry form. It does not confirm project acceptance, capacity, timing, a quotation or a regulatory outcome.
CMO
Manufacturing and supply discussion
For commercial manufacturing, scale-up or supply planning. Start with the dosage form, presentation, target market and milestone that makes a first review useful.
Discuss a CMO projectCDMO
Development-to-manufacturing discussion
For projects that may need formulation or process work, scale-up, analytical and regulatory planning, and a controlled route into manufacturing.
Discuss a CDMO projectTechnology transfer
Controlled transfer planning
For teams assessing a transfer of manufacturing knowledge or a product route. Scope, responsibilities, evidence and confidentiality need to be agreed before technical exchange.
Discuss a transfer projectDecision resources
Use the right decision resource
Public capability and evidence
Review Hainan Hailing's public facts, dosage-form platforms and careful regulatory wording.
Open public facts →Project evaluation pathway
See how an initial screen moves through NDA, diligence, transfer and commercial readiness.
Open project pathway →Quality and regulatory partnership
Understand how quality responsibilities, evidence and communications should be controlled.
Open quality resource →Technical due diligence guides
Compare CMO, CDMO and technology transfer before preparing a project brief; then use the broader sterile-manufacturing and diligence guides.
Compare CMO, CDMO and technology transfer →Open insight library →
Non-confidential project brief template
Use an editable template to prepare a focused first-contact summary without sending sensitive materials.
Editable DOCX ↓PDF reference ↓
After submission
What happens after a preliminary assessment request
Acknowledgement
A valid business inquiry is normally acknowledged within three business days. This is not project acceptance or a quotation.
Clarification
The first response may ask for a clearer non-confidential description of the market, dosage form, stage, timing or intended cooperation model.
Mutual NDA
Where there is a plausible project fit, the parties can agree a confidentiality route before technical or commercial materials are exchanged.
Controlled diligence
Technical, quality, regulatory, supply and commercial evidence can then be reviewed against an agreed request list, access scope and decision plan.
CMO · CDMO · Technology Transfer
Start with a focused, non-confidential project brief.
The secure inquiry form captures the minimum information needed to assess project fit. It is not a quotation, product commitment or regulatory opinion.
Prefer to begin by email?
Use a five-point, non-confidential project note.
A concise first email can be easier than assembling a full package. It should give enough context for a responsible preliminary review, without asking either side to disclose controlled technical or commercial information.
Email stevenyiqingli@foxmail.comValid business inquiries are normally acknowledged within three business days.
Sterile CMO due diligence
Assess sterile injectable project fit before technical disclosure
For sterile injectable or lyophilized product opportunities, a responsible first assessment tests public legal scope, product-to-train fit, sterile-processing controls, quality evidence and transfer readiness before either party shares controlled technical material.
Use the sterile injectable CMO due-diligence checklist →